-
-
-
-
-
-
-
RBC Capital Downgrades aTyr Pharma (ATYR) to Sector Perform
-
-
-
-
-
-
-
aTyr Pharma (ATYR) Halted, News Pending
-
-
-
-
-
-
-
aTyr Pharma completes Phase 3 sarcoidosis drug trial enrollment
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)
-
-
-
-
-
-
-
aTyr Pharma (ATYR) Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
-
-
-
-
-
-
-
Lucid Capital Markets Starts aTyr Pharma (ATYR) at Buy
-
-
-
-
-
-
-
aTyr Pharma (ATYR) Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
-
444,654 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

